Related Experiment Video
Updated: Jun 10, 2026
05:39
Acupoint Needle-Embedding Combined with Ironing Therapy for Postoperative Pain After Anal Surgery
Published on: June 23, 2023
[Pain therapy in proctology]
Johannes Jongen1, Imme Kahl, Annette Pflug
1Abteilung chirurgische Proktologie der Park-Klinik Kiel, Beselerallee 67, 24105 Kiel. jjongen@proktologie-kiel.de
Medizinische Monatsschrift Fur Pharmazeuten
|August 7, 2010
Summary
Effective treatment for considerable anorectal pain requires accurate diagnosis and stool consistency (Bristol stool form scale type 4). Diclofenac is recommended, with metamizole or tramadol added if pain persists, alongside topical agents for specific cases.
Area of Science:
- Gastroenterology and Pain Management
Context:
- Anorectal pain presents significant patient discomfort.
- Effective management strategies are crucial for improving quality of life.
Purpose:
- To outline diagnostic considerations and treatment protocols for anorectal pain.
- To provide guidance on pharmacologic and topical interventions.
Summary:
- Accurate diagnosis is paramount before initiating treatment for anorectal pain.
- Maintaining normal stool consistency (Bristol stool form scale type 4) is essential.
- Diclofenac (50 mg three times daily) is a recommended first-line treatment.
- Adjunctive therapies including metamizole, tramadol, topical agents (e.g., glyceryl trinitrate, botulinum toxin A), and topical steroids for edema may be considered.
Impact:
- Provides a structured approach to managing anorectal pain.
- Highlights the importance of stool form in treatment efficacy.
- Offers a tiered treatment strategy based on pain severity and specific conditions.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.